TY - JOUR
T1 - Current progress in antivascular tumor therapy
AU - Ho, Yi Ju
AU - Wang, Tzu Chia
AU - Fan, Ching Hsiang
AU - Yeh, Chih Kuang
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/10
Y1 - 2017/10
N2 - The tumor vasculature transports oxygen, nutrients and drugs for crucial roles in tumor therapy. Antivascular therapy directly targets existing tumor vessels to reduce blood perfusion and then inhibit tumor growth. Vascular disrupting agents and ultrasound-stimulated microbubble destruction use chemical toxicity and physical effect, respectively, to damage vascular endothelial cells for antivascular therapy. Moreover, antivascular therapy can break vessel wall barriers and change the tumor microenvironment to compensate for the limitations of conventional chemotherapy or radiotherapy. This review presents current progress and an overview of antivascular therapy, which can inform the development and application in cancer research. This review presents current progress and an overview of antivascular therapy to inform its development and application in cancer research.
AB - The tumor vasculature transports oxygen, nutrients and drugs for crucial roles in tumor therapy. Antivascular therapy directly targets existing tumor vessels to reduce blood perfusion and then inhibit tumor growth. Vascular disrupting agents and ultrasound-stimulated microbubble destruction use chemical toxicity and physical effect, respectively, to damage vascular endothelial cells for antivascular therapy. Moreover, antivascular therapy can break vessel wall barriers and change the tumor microenvironment to compensate for the limitations of conventional chemotherapy or radiotherapy. This review presents current progress and an overview of antivascular therapy, which can inform the development and application in cancer research. This review presents current progress and an overview of antivascular therapy to inform its development and application in cancer research.
UR - http://www.scopus.com/inward/record.url?scp=85021304789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021304789&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2017.06.001
DO - 10.1016/j.drudis.2017.06.001
M3 - Review article
C2 - 28625610
AN - SCOPUS:85021304789
SN - 1359-6446
VL - 22
SP - 1503
EP - 1515
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 10
ER -